Third Rock Ventures V, L.P. 4
4 · Rapport Therapeutics, Inc. · Filed May 13, 2026
Research Summary
AI-generated summary of this filing
Rapport Therapeutics (RAPP) 10% Owner Third Rock Ventures V Sells Shares
What Happened
Third Rock Ventures V, L.P. (a reported >10% holder) sold 133,618 shares of Rapport Therapeutics (RAPP) in an open-market/private sale on May 11, 2026. The weighted-average price was $40.24 per share, producing proceeds of approximately $5,377,323. This transaction was a sale (routine disposition by an institutional holder), not a purchase.
Key Details
- Transaction date: 2026-05-11; Filing date: 2026-05-13 (appears timely — within two business days).
- Price: weighted average $40.24; individual sale prices ranged from $40.00 to $40.665 (report offers to provide per-price breakdown on request).
- Shares sold: 133,618; proceeds ~ $5.38 million.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Notable footnotes: transaction executed under a Rule 10b5-1 trading plan dated Nov 21, 2025 (F1); weighted-price range disclosed with offer to provide further breakdown (F2); filing includes customary beneficial-ownership disclaimers for TRV entities (F3, F4).
- Nature of filer: Institutional/venture investor (10% owner), not company management or director.
Context
This was an institutional sale executed under a pre-established 10b5-1 plan, which typically indicates pre-set selling instructions rather than ad-hoc insider trading. The filing includes standard partnership disclaimers about beneficial ownership among related Third Rock entities; treat this as VC/investor liquidity rather than a direct signal from company executives.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-05-11$40.24/sh−133,618$5,377,323→ 6,299,097 total
- 969,218(indirect: By Third Rock Ventures VI, L.P.)
Common Stock
[F4]
Footnotes (4)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025, previously adopted by the Reporting Person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
- [F3]These shares are directly held by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
- [F4]The shares are held directly by Third Rock Ventures VI, L.P. ("TRV VI"). The general partner of TRV VI is Third Rock Ventures GP VI, L.P. ("TRV GP VI"). The general partner of TRV GP VI is TRV GP VI, LLC ("TRV GP VI LLC"). Each of TRV GP VI, and TRV GP VI LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between any TRV V related parties and any TRV VI related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.